Abstract
In this study of 500 patients with breast carcinoma, we have prospectively assessed the role of preoperative CA 15-3 as a marker of disease burden over a 7 year period. CA 15-3 levels at presentation correlate with stage of disease, tumour size, lymph node status, the presence of metastases and lymphocyte infiltration into the tumour. CA 15-3 alone is not an independent prognostic indicator, although a serum level of > 40 U ml-1 has a positive predictive value of 83% for the presence of advanced disease. We recommend the routine use of this marker in the preoperative assessment of primary breast carcinoma.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gion M., Mione R., Nascimben O., Valsecchi M., Gatti C., Leon A., Bruscagnin G. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer. 1991 May;63(5):809–813. doi: 10.1038/bjc.1991.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harris J. R., Lippman M. E., Veronesi U., Willett W. Breast cancer (1) N Engl J Med. 1992 Jul 30;327(5):319–328. doi: 10.1056/NEJM199207303270505. [DOI] [PubMed] [Google Scholar]
- Hayes D. F., Sekine H., Ohno T., Abe M., Keefe K., Kufe D. W. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985 May;75(5):1671–1678. doi: 10.1172/JCI111875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayes D. F., Zurawski V. R., Jr, Kufe D. W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct;4(10):1542–1550. doi: 10.1200/JCO.1986.4.10.1542. [DOI] [PubMed] [Google Scholar]
- Hilkens J., Buijs F., Hilgers J., Hageman P., Calafat J., Sonnenberg A., van der Valk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984 Aug 15;34(2):197–206. doi: 10.1002/ijc.2910340210. [DOI] [PubMed] [Google Scholar]
- Hilkens J., Kroezen V., Bonfrer J. M., De Jong-Bakker M., Bruning P. F. MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 1986 May;46(5):2582–2587. [PubMed] [Google Scholar]
- Kerin M. J., McAnena O. J., O'Malley V. P., Grimes H., Given H. F. CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg. 1989 Aug;76(8):838–839. doi: 10.1002/bjs.1800760826. [DOI] [PubMed] [Google Scholar]
- Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984 Fall;3(3):223–232. doi: 10.1089/hyb.1984.3.223. [DOI] [PubMed] [Google Scholar]
- Pons-Anicet D. M., Krebs B. P., Mira R., Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer. 1987 May;55(5):567–569. doi: 10.1038/bjc.1987.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Robertson J. F., Pearson D., Price M. R., Selby C., Badley R. A., Pearson J., Blamey R. W., Howell A. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer. 1990;26(11-12):1127–1132. doi: 10.1016/0277-5379(90)90268-x. [DOI] [PubMed] [Google Scholar]
- Schmidt-Rhode P., Schulz K. D., Sturm G., Raab-Frick A., Prinz H. CA 15.3 as a tumour marker in breast cancer. Int J Biol Markers. 1987 Sep-Dec;2(3):135–142. doi: 10.1177/172460088700200301. [DOI] [PubMed] [Google Scholar]